CL2020002755A1 - Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. - Google Patents

Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.

Info

Publication number
CL2020002755A1
CL2020002755A1 CL2020002755A CL2020002755A CL2020002755A1 CL 2020002755 A1 CL2020002755 A1 CL 2020002755A1 CL 2020002755 A CL2020002755 A CL 2020002755A CL 2020002755 A CL2020002755 A CL 2020002755A CL 2020002755 A1 CL2020002755 A1 CL 2020002755A1
Authority
CL
Chile
Prior art keywords
nucleic acids
encode
recombinant nucleic
proteins
cosmetic proteins
Prior art date
Application number
CL2020002755A
Other languages
English (en)
Inventor
Suma Krishnan
Pooja Agarwal
Trevor Parry
Original Assignee
Krystal Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krystal Biotech Inc filed Critical Krystal Biotech Inc
Publication of CL2020002755A1 publication Critical patent/CL2020002755A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16631—Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)

Abstract

La presente descripción proporciona ácidos nucleicos recombinantes que comprenden uno o más polinucleótidos que codifican una o más proteínas cosméticas (por ejemplo, una o más proteínas de colágeno humanas); virus que comprenden los ácidos nucleicos recombinantes; composiciones (por ejemplo, formulaciones cosméticas) que comprenden los virus y/o ácidos nucleicos recombinantes; métodos para utilizarlos; y productos de elaboración o kits de estos.
CL2020002755A 2018-04-27 2020-10-23 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. CL2020002755A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862663476P 2018-04-27 2018-04-27

Publications (1)

Publication Number Publication Date
CL2020002755A1 true CL2020002755A1 (es) 2021-01-29

Family

ID=68291937

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2020002755A CL2020002755A1 (es) 2018-04-27 2020-10-23 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2023001338A CL2023001338A1 (es) 2018-04-27 2023-05-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000409A CL2024000409A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000410A CL2024000410A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000411A CL2024000411A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.

Family Applications After (4)

Application Number Title Priority Date Filing Date
CL2023001338A CL2023001338A1 (es) 2018-04-27 2023-05-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000409A CL2024000409A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000410A CL2024000410A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000411A CL2024000411A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.

Country Status (13)

Country Link
US (2) US10786438B2 (es)
EP (1) EP3810149A4 (es)
JP (2) JP2021521894A (es)
KR (1) KR20210005141A (es)
CN (1) CN112041434A (es)
AU (2) AU2019260757B2 (es)
BR (1) BR112020021804A2 (es)
CA (1) CA3095187A1 (es)
CL (5) CL2020002755A1 (es)
CO (1) CO2020013588A2 (es)
MX (1) MX2020011257A (es)
SG (1) SG11202009895TA (es)
WO (1) WO2019210219A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017176336A1 (en) 2016-04-08 2017-10-12 Krystal Biotech, LLC Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
EP3775236A1 (en) 2018-04-12 2021-02-17 Krystal Biotech, LLC Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
CN113454105A (zh) 2019-02-08 2021-09-28 克里斯托生物技术股份有限公司 用于递送cftr多肽的组合物和方法
US20210189427A1 (en) 2019-12-20 2021-06-24 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
WO2021175293A1 (zh) * 2020-03-05 2021-09-10 北京唯源立康生物科技有限公司 一种单纯疱疹病毒及其用途
CN111423516B (zh) * 2020-04-01 2022-02-11 广州佰斯伦医疗器械有限公司 一种蛋白及其在创口修复及抑菌中的应用
CN112746076B (zh) * 2020-12-28 2023-05-12 中吉智药(南京)生物技术有限公司 一种密码子优化的col7a1基因及慢病毒和应用
CN117412986A (zh) 2021-04-02 2024-01-16 克里斯托生物技术股份有限公司 用于癌症疗法的病毒载体
CN114195884B (zh) * 2021-10-27 2024-03-29 禾美生物科技(浙江)有限公司 一种重组人源胶原蛋白及其制备方法
CN114656572B (zh) * 2022-02-25 2024-07-19 北京大学第一医院 一种bp180抗体快速检测试剂盒及其制备方法
CN117143223B (zh) * 2022-08-23 2024-03-08 山西锦波生物医药股份有限公司 一种生物合成人体结构性材料的制备方法
CN117230103B (zh) * 2023-09-25 2024-04-19 爱光生物医药(南昌)有限公司 17型人源化胶原蛋白及其蛋白支架、填充材料及应用
CN117402235B (zh) * 2023-10-25 2024-06-11 山西锦波生物医药股份有限公司 生物合成人体结构性材料iv型胶原蛋白的制备方法
CN117986353B (zh) * 2024-02-02 2024-08-30 西安巨子生物基因技术股份有限公司 重组人xvii型胶原蛋白、其制备方法及应用
CN117866077B (zh) * 2024-03-13 2024-05-28 北京未名拾光生物技术有限公司 重组xvii型胶原蛋白及其表达体系
CN117986389B (zh) * 2024-04-02 2024-06-07 百肽德医药生物科技(广东)有限公司 一种重组人源化xvii型胶原蛋白、制备方法及应用
CN118324899B (zh) * 2024-06-13 2024-08-20 江苏亨瑞生物医药科技有限公司 一种重组xvii型人源化胶原蛋白、制备方法及其应用
CN118388666B (zh) * 2024-06-25 2024-09-20 山东美瑞生物技术有限公司 一种促进皮肤胶原蛋白和弹性蛋白再生的多肽及制备方法
CN118480554B (zh) * 2024-07-16 2024-10-18 苏州拾光医药生物科技有限公司 重组弹性蛋白及其表达体系和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
DE69839243T2 (de) 1997-04-10 2009-04-30 University Of Southern California, Los Angeles Sich an extrazelluläre matrixbestandteile anbindende modifizierte proteine
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9715085D0 (en) 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
US6106826A (en) 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
WO1999064094A1 (en) 1998-06-12 1999-12-16 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
EP1141338A4 (en) 1998-12-31 2002-09-25 Arch Dev Corp RECOMBINANT HERPES SIMPLEX VIRUS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES
CA2399371A1 (en) * 1999-11-12 2001-05-17 Fibrogen, Inc. Animal collagens and gelatins
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
EP1356071B1 (en) 2000-11-28 2007-11-21 The University of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
US8703703B2 (en) * 2006-12-20 2014-04-22 University Of Central Flordia Research Foundation, Inc. MCPIP as wound therapy
JP2008174459A (ja) * 2007-01-16 2008-07-31 Maruzen Pharmaceut Co Ltd 抗老化剤、並びに皮膚外用剤及び美容用飲食品
US20080299182A1 (en) 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
ES2590461T3 (es) 2010-07-02 2016-11-22 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii La transcriptasa inversa de la telomerasa como protección frente al envejecimiento
CN102212559B (zh) 2011-04-14 2014-04-09 郑州威瑞生物技术有限公司 一种重组的hsv扩增子载体及其用途
ES2670495T3 (es) 2011-10-11 2018-05-30 Inserm - Institut National De La Santé Et De La Recherche Médicale Tratamiento de salto de exones para epidermólisis ampollosa distrófica
GB201202561D0 (en) 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9314505B2 (en) 2012-05-18 2016-04-19 Otago Innovation Limited Combination treatments and compositions for wound healing comprising viral VEGF
WO2014134412A1 (en) 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
KR102649583B1 (ko) 2013-07-17 2024-03-20 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 효율적인 유전자 전달 적용을 위한 비독성 hsv 벡터 및 이의 생산을 위한 보완 세포
MX2016009771A (es) * 2014-01-31 2016-11-14 Factor Bioscience Inc Metodos y productos para la produccion y administracion de acido nucleico.
JP2015221759A (ja) * 2014-05-22 2015-12-10 株式会社東洋新薬 コラーゲン合成促進剤、ヒアルロン酸合成促進剤及びセラミド合成促進剤
FR3021541B1 (fr) 2014-05-28 2017-10-27 Oreal Procede cosmetique pour attenuer les rides
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
MX369749B (es) 2015-03-05 2019-11-20 Avon Prod Inc Método cosmético para reducir las señales dermatológicas de envejecimiento.
PT3432912T (pt) 2016-03-25 2023-03-02 Periphagen Inc Vetores de hsv de elevada transdução
WO2017176336A1 (en) 2016-04-08 2017-10-12 Krystal Biotech, LLC Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
MA45492A (fr) 2016-06-23 2019-05-01 Hopitaux Paris Assist Publique Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
EP3775236A1 (en) * 2018-04-12 2021-02-17 Krystal Biotech, LLC Compositions and methods for the treatment of autosomal recessive congenital ichthyosis

Also Published As

Publication number Publication date
CL2024000410A1 (es) 2024-08-23
BR112020021804A2 (pt) 2021-02-23
CO2020013588A2 (es) 2020-11-10
US10786438B2 (en) 2020-09-29
CL2023001338A1 (es) 2023-10-20
MX2020011257A (es) 2021-01-15
CA3095187A1 (en) 2019-10-31
CL2024000409A1 (es) 2024-08-23
JP2021521894A (ja) 2021-08-30
AU2023285844A1 (en) 2024-01-25
SG11202009895TA (en) 2020-11-27
AU2019260757B2 (en) 2023-09-28
WO2019210219A1 (en) 2019-10-31
JP2024056823A (ja) 2024-04-23
US20190328644A1 (en) 2019-10-31
EP3810149A4 (en) 2022-08-24
EP3810149A1 (en) 2021-04-28
CL2024000411A1 (es) 2024-08-23
KR20210005141A (ko) 2021-01-13
US20210045988A1 (en) 2021-02-18
AU2019260757A1 (en) 2020-12-03
CN112041434A (zh) 2020-12-04

Similar Documents

Publication Publication Date Title
CL2020002755A1 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
NI201800121A (es) Proteínas de fusión gdf15 y usos de estas
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
CL2020003176A1 (es) Novedosas proteínas de la cápside del virus adenoasociado (divisional sol. 201900167).
CO2018006301A2 (es) Mutantes de proteína f de rsv
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
CO2020013050A2 (es) Enzimas quinureninasa humanas y sus usos
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
BR112019008781A2 (pt) poxvírus quiméricos sintéticos
BR112018008840A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112018073007A2 (pt) terapia de combinação inicial:reforço
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos